Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥5 or Framingham risk >20: Post hoc analyses of the JUPITER trial requested by European health authorities

European Heart Journal

Volumn 32, Issue 1, 2011, Pages 75-83

  Koenig, Wolfgang ^a   Ridker, Paul M ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

C reactive protein; Coronary heart disease; High risk; Rosuvastatin

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CORONARY RISK; DIABETES MELLITUS; EUROPE; FEMALE; FOLLOW UP; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOPATHY; MYOSITIS; POST HOC ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; STROKE; UNSTABLE ANGINA PECTORIS;

AGED; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRIMARY PREVENTION; PYRIMIDINES; RISK ASSESSMENT; RISK FACTORS; STROKE; SULFONAMIDES;

EID: 78651287065     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq370     Document Type: Article

References (18)

1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
2. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial for rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851-1861.
3. Crestor prescribing information in the United States. http://www1.astrazeneca-us. com/pi/crestor.pdf (5 May 2010).
4. Crestor prescribing information in the UK. http://www.medicines.org.uk/ EMC/ medicine/11976/SPC/Crestor+5mg%2c+10mg%2c+20mg+and+40mg+film-coated+ tablets/ (24 May 2010).
5. Pearson TA, Mensah GA, AlexanDer RW, AnDerson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
6. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003;108:2292-2297.
7. Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization. http://www.meddramsso.com/index.asp (14 April 2010).
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
9. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497.
10. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM; SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
11. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-1610.
12. Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007;107:433-443.
13. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in olDer persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010;152:488-496.
14. The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-140.
15. Committee for Medicinal Products for Human Use. Guideline on the Evaluation of Medicinal Products for Cardiovascular Disease Prevention. Doc ref. EMEA/ CHMP/EWP/311890/2007, published London 25 September 2008.
16. ESC Clinical Practice Guidelines. http://www.escardio.org/guidelines- surveys/esc-guidelines/Pages/cvd-prevention.aspx (14 April 2010).
17. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ö stergren J.; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.